You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 660 Phase 2 Study to evaluate the triplet combination of pemetrexed plus etrumadenant and zimberelimab in patients with previously treated advanced or MTAP-deficient metastatic urothelial carcinoma (mUC)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
660 Phase 2 Study to evaluate the triplet combination of pemetrexed plus etrumadenant and zimberelimab in patients with previously treated advanced or MTAP-deficient metastatic urothelial carcinoma (mUC)

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023194016
Dec 202334012
Jan 20243101
Feb 20242602
Mar 20243401
Apr 20242402
May 20241000
Jun 20242304
Jul 20241401
Aug 20242402
Sep 20242803
Oct 20242007
Nov 20244603
Dec 20242004
Jan 20254108
Feb 20251206
Mar 2025007
Apr 2025001
May 2025002
Jun 2025105
Total582087